drugset / Trial / NCT02227368

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

NCT02227368

Phase 2 Terminated 40 enrolled AstraZeneca CPC Clinical Research · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have undergone endovascular revascularization for moderate to severe claudication or ischemic rest pain.

Timeline

Start
2014-10-20
Primary completion
2016-05-23
Completion
2016-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 100 mg
Subject Ticagrelor Small molecule 90 mg